Trials / Terminated
TerminatedNCT00475917
A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Subjects With Advanced Malignancies
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Exelixis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine a safe dose of XL844 in combination with gemcitabine, how often it should be taken, and how well people with cancer tolerate the combination of gemcitabine and XL844.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XL844 | Gelatin capsules supplied as 5-mg, 25-mg, and 100-mg strengths; twice-weekly dosing. |
| DRUG | Gemcitabine | once-weekly 30-minute IV infusion |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2007-05-21
- Last updated
- 2015-08-21
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00475917. Inclusion in this directory is not an endorsement.